Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7324
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    83.79
    +0.22 (+0.26%)
     

  • Bitcoin CAD

    87,984.66
    +138.85 (+0.16%)
     

  • CMC Crypto 200

    1,390.19
    +7.62 (+0.55%)
     

  • GOLD FUTURES

    2,345.00
    +2.50 (+0.11%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,766.50
    +199.00 (+1.13%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    38,059.84
    +431.36 (+1.15%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Today’s Research Reports on Acerus Pharmaceuticals, Aphria Inc., Oncolytics Biotech Inc. and GLG Life Tech Corporation

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / November 29, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Acerus Pharmaceuticals Corporation
https://rdinvesting.com/news/?ticker=ASP.TO

Aphria Inc.
https://rdinvesting.com/news/?ticker=APH.TO

Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO

GLG Life Tech Corporation
https://rdinvesting.com/news/?ticker=GLG.TO

ADVERTISEMENT

Acerus Pharmaceuticals Corporation's stock fell 22.00% Tuesday, to close the day at $0.39. The stock recorded a trading volume of 4,985,014 shares, which was above its three months average volume of 441,000 shares. In the last year, Acerus Pharmaceuticals Corporation's shares have traded in a range of 0.10 - 9.85. The share price has gained 290.00% from its 52-week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.15 is greater than its 200-day moving average of $0.13. Shares of Acerus Pharmaceuticals have gained approximately 188.89 percent year-to-date.

Access RDI's Acerus Pharmaceuticals Corporation Research Report at:
https://rdinvesting.com/news/?ticker=ASP.TO

On Tuesday, shares in Aphria Inc. recorded a trading volume of 9,034,910 shares, which was above the three months average volume of 2,441,893 shares. The stock ended the day 4.89% lower at 11.47. The share price has gained 182.51% from its 52-week low with a 52-week trading range of 4.06 - 12.74.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $8.10 is greater than its 200-day moving average of $6.50. Shares of Aphria Inc. are trading at a Price to Earnings ratio of 80.21. Shares of Aphria have gained approximately 83.52 percent year-to-date.

Access RDI's Aphria Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APH.TO

Oncolytics Biotech Inc.'s stock moved 1.49% higher Tuesday, to close the day at $0.68. The stock recorded a trading volume of 152,800 shares, which was below its three months average volume of 246,931 shares. In the last year, Oncolytics Biotech Inc.'s shares have traded in a range of 0.19 - 1.13. The share price has gained 257.89% from its 52-week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.61 is greater than its 200-day moving average of $0.57. Shares of Oncolytics Biotech have gained approximately 156.6 percent year-to-date.

Access RDI's Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO

On Tuesday, shares in GLG Life Tech Corporation recorded a trading volume of 16,100 shares, which was above the three months average volume of 13,173 shares. The stock ended the day 4.13% lower at 1.16. The share price has gained 510.53% from its 52-week low with a 52-week trading range of 0.19 - 1.60.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.11 is greater than its 200-day moving average of $0.72. Shares of GLG Life Tech have gained approximately 393.62 percent year-to-date.

Access RDI's GLG Life Tech Corporation Research Report at:
https://rdinvesting.com/news/?ticker=GLG.TO

Our Actionable Research on Acerus Pharmaceuticals Corporation (TSX:ASP.TO), Aphria Inc. (TSX:APH.TO), Oncolytics Biotech Inc. (TSX:ONC.TO) and GLG Life Tech Corporation (TSX:GLG.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com